Glepaglutide_product_DataBase

Bioactivity	Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease[1][2][3].
Target	GLP-2R
In Vivo	Glepaglutide (200 and 400 nmol/kg, s.c., twice a day for 14 days) shows intestinotrophic effect in rats with small intestinal inflammation[3]. Animal Model:
Name	Glepaglutide
CAS	914009-86-2
Sequence	His-Gly-Glu-Gly-Thr-Phe-Ser-Ser-Glu-Leu-Ala-Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Lys-Lys-Lys-Lys-Lys-Lys-NH2
Shortening	HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2
Formula	C197H325N53O55
Molar Mass	4316.08
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Naimi RM, et al. a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. [2]. Janssen P, et al. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2013 Jan;37(1):18-36. [3]. Jolanta Skarbaliene, et al. ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn's Disease Model. Gastroenterology, 2011, 140(5): S519.

PeptideDB